Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unrese
A phase 2 trial of Telisotuzumab adizutecan, Bevacizumab, Leucovorin in colorectal cancer, run by AbbVie, active and no longer recruiting.
Overview
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab is a phase 2 interventional study registered as NCT06107413 by AbbVie, with 280 participants planned, started 2023-11-12 and due to reach its primary completion in 2026-12. Interventions recorded: ABBV-400, Bevacizumab, Folinic Acid, Fluorouracil, Irinotecan. Conditions listed: Unresectable Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil,
Shares Telisotuzumab adizutecan, Fluorouracil (5-FU), AbbVie (incl. ImmunoGen, Capstan), Bevacizumab.
- TrialA Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
Shares Telisotuzumab adizutecan, AbbVie (incl. ImmunoGen, Capstan), Colorectal cancer.
- TrialA Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone o
Shares Telisotuzumab adizutecan, AbbVie (incl. ImmunoGen, Capstan), Colorectal cancer.
- TrialA Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
Shares Telisotuzumab adizutecan, AbbVie (incl. ImmunoGen, Capstan), Colorectal cancer.
- TrialA Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Fluorouracil (5-FU), Bevacizumab, Colorectal cancer.
- TrialA Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer
Shares Leucovorin (folinic acid), FOLFIRI (5-FU, leucovorin, irinotecan), Fluorouracil (5-FU), Colorectal cancer.
- TrialA Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Shares Telisotuzumab adizutecan, AbbVie (incl. ImmunoGen, Capstan).
- TrialA Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Shares Telisotuzumab adizutecan, AbbVie (incl. ImmunoGen, Capstan).